Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs

Suqin Guo, Yongliang Cui, Lishan He, Liang Zhang, Zhen Cao, Wei Zhang, Rui Zhang, Guiyu Tan, Baomin Wang, Liwang Cui

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Artemether is one of the artemisinin derivatives that are active ingredients in antimalarial drugs. Counterfeit and substandard antimalarial drugs have become a serious problem, which demands reliable analytical tools and implementation of strict regulation of drug quality. Structural similarity among artemisinin analogs is a challenge to develop immunoassays that are specific to artemisinin derivatives. To produce specific antibodies to artemether, we used microbial fermentation of artemether to obtain 9-hydroxyartemether, which was subsequently used to prepare a 9-Osuccinylartemether hapten for conjugation with ovalbumin as the immunogen. A monoclonal antibody (mAb), designated as 2G12E1, was produced with high specificity to artemether. 2G12E1 showed low cross reactivities to dihydroartemisinin, artemisinin, artesunate and other major antimalarial drugs. An indirect competitive enzyme linked immunosorbent assay (icELISA) developed showed a concentration causing 50% of inhibition for artemether as 3.7 ng mL-1 and a working range of 0.7-19 ng mL-1. The icELISA was applied for determination of artemether content in different commercial drugs and the results were comparable to those determined by high-performance liquid chromatography analysis. In comparison with reported broad cross activity of anti-artemisinin mAbs, the most notable advantage of the 2G12E1-based ELISA is its high specificity to artemether only.

Original languageEnglish (US)
Article numbere79154
JournalPloS one
Volume8
Issue number11
DOIs
StatePublished - Nov 13 2013

Fingerprint

artemisinin
antimalarials
Antimalarials
monoclonal antibodies
Monoclonal Antibodies
enzyme-linked immunosorbent assay
Immunosorbents
dihydroartemisinin
Enzyme-Linked Immunosorbent Assay
chemical derivatives
drugs
haptens
Assays
ovalbumin
active ingredients
immunoassays
cross reaction
Derivatives
Haptens
Drug and Narcotic Control

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Guo, Suqin ; Cui, Yongliang ; He, Lishan ; Zhang, Liang ; Cao, Zhen ; Zhang, Wei ; Zhang, Rui ; Tan, Guiyu ; Wang, Baomin ; Cui, Liwang. / Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs. In: PloS one. 2013 ; Vol. 8, No. 11.
@article{9c314d66906f4601b9ef27127a9b5390,
title = "Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs",
abstract = "Artemether is one of the artemisinin derivatives that are active ingredients in antimalarial drugs. Counterfeit and substandard antimalarial drugs have become a serious problem, which demands reliable analytical tools and implementation of strict regulation of drug quality. Structural similarity among artemisinin analogs is a challenge to develop immunoassays that are specific to artemisinin derivatives. To produce specific antibodies to artemether, we used microbial fermentation of artemether to obtain 9-hydroxyartemether, which was subsequently used to prepare a 9-Osuccinylartemether hapten for conjugation with ovalbumin as the immunogen. A monoclonal antibody (mAb), designated as 2G12E1, was produced with high specificity to artemether. 2G12E1 showed low cross reactivities to dihydroartemisinin, artemisinin, artesunate and other major antimalarial drugs. An indirect competitive enzyme linked immunosorbent assay (icELISA) developed showed a concentration causing 50{\%} of inhibition for artemether as 3.7 ng mL-1 and a working range of 0.7-19 ng mL-1. The icELISA was applied for determination of artemether content in different commercial drugs and the results were comparable to those determined by high-performance liquid chromatography analysis. In comparison with reported broad cross activity of anti-artemisinin mAbs, the most notable advantage of the 2G12E1-based ELISA is its high specificity to artemether only.",
author = "Suqin Guo and Yongliang Cui and Lishan He and Liang Zhang and Zhen Cao and Wei Zhang and Rui Zhang and Guiyu Tan and Baomin Wang and Liwang Cui",
year = "2013",
month = "11",
day = "13",
doi = "10.1371/journal.pone.0079154",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Guo, S, Cui, Y, He, L, Zhang, L, Cao, Z, Zhang, W, Zhang, R, Tan, G, Wang, B & Cui, L 2013, 'Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs', PloS one, vol. 8, no. 11, e79154. https://doi.org/10.1371/journal.pone.0079154

Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs. / Guo, Suqin; Cui, Yongliang; He, Lishan; Zhang, Liang; Cao, Zhen; Zhang, Wei; Zhang, Rui; Tan, Guiyu; Wang, Baomin; Cui, Liwang.

In: PloS one, Vol. 8, No. 11, e79154, 13.11.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of a specific monoclonal antibody-based elisa to measure the artemether content of antimalarial drugs

AU - Guo, Suqin

AU - Cui, Yongliang

AU - He, Lishan

AU - Zhang, Liang

AU - Cao, Zhen

AU - Zhang, Wei

AU - Zhang, Rui

AU - Tan, Guiyu

AU - Wang, Baomin

AU - Cui, Liwang

PY - 2013/11/13

Y1 - 2013/11/13

N2 - Artemether is one of the artemisinin derivatives that are active ingredients in antimalarial drugs. Counterfeit and substandard antimalarial drugs have become a serious problem, which demands reliable analytical tools and implementation of strict regulation of drug quality. Structural similarity among artemisinin analogs is a challenge to develop immunoassays that are specific to artemisinin derivatives. To produce specific antibodies to artemether, we used microbial fermentation of artemether to obtain 9-hydroxyartemether, which was subsequently used to prepare a 9-Osuccinylartemether hapten for conjugation with ovalbumin as the immunogen. A monoclonal antibody (mAb), designated as 2G12E1, was produced with high specificity to artemether. 2G12E1 showed low cross reactivities to dihydroartemisinin, artemisinin, artesunate and other major antimalarial drugs. An indirect competitive enzyme linked immunosorbent assay (icELISA) developed showed a concentration causing 50% of inhibition for artemether as 3.7 ng mL-1 and a working range of 0.7-19 ng mL-1. The icELISA was applied for determination of artemether content in different commercial drugs and the results were comparable to those determined by high-performance liquid chromatography analysis. In comparison with reported broad cross activity of anti-artemisinin mAbs, the most notable advantage of the 2G12E1-based ELISA is its high specificity to artemether only.

AB - Artemether is one of the artemisinin derivatives that are active ingredients in antimalarial drugs. Counterfeit and substandard antimalarial drugs have become a serious problem, which demands reliable analytical tools and implementation of strict regulation of drug quality. Structural similarity among artemisinin analogs is a challenge to develop immunoassays that are specific to artemisinin derivatives. To produce specific antibodies to artemether, we used microbial fermentation of artemether to obtain 9-hydroxyartemether, which was subsequently used to prepare a 9-Osuccinylartemether hapten for conjugation with ovalbumin as the immunogen. A monoclonal antibody (mAb), designated as 2G12E1, was produced with high specificity to artemether. 2G12E1 showed low cross reactivities to dihydroartemisinin, artemisinin, artesunate and other major antimalarial drugs. An indirect competitive enzyme linked immunosorbent assay (icELISA) developed showed a concentration causing 50% of inhibition for artemether as 3.7 ng mL-1 and a working range of 0.7-19 ng mL-1. The icELISA was applied for determination of artemether content in different commercial drugs and the results were comparable to those determined by high-performance liquid chromatography analysis. In comparison with reported broad cross activity of anti-artemisinin mAbs, the most notable advantage of the 2G12E1-based ELISA is its high specificity to artemether only.

UR - http://www.scopus.com/inward/record.url?scp=84893381413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893381413&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079154

DO - 10.1371/journal.pone.0079154

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79154

ER -